Operations Excellence - Business Process Automation Gets Going - BioPharm International

ADVERTISEMENT

Operations Excellence
Business Process Automation Gets Going


BioPharm International


In August, Tefen Ltd., founder of the BioPharma Operations Excellence Consortium, and BioPharm International announced in this column that we would work together to provide periodic coverage of consortium activity.

The consortium held a quarterly meeting on October 2nd, hosted by IDEC Pharmaceuticals at its San Diego, CA headquarters. About 20 leading biopharma companies sent over 30 representatives to the full-day session. The meeting focused on automation and information technology (IT) solutions and how they are being put in place to support operational improvement within the industry.

Tefen led off the day with a summary of automation-related findings from its recent industry-wide benchmarking study (published as a BioPharm International supplement, September 2003). The general conclusion from the benchmark study is that business-process automation and IT systems are not yet considered crucial to achieving operational efficiency, but their importance is expected to increase significantly during the next 5 to 10 years. Tefen found that only 36% of polled industry executives feel that automation and IT currently play a critical role in their operations. Slightly more, 37%, recognize IT is necessary but its not the solution to everything.

In response to a question about the future of a paperless environment, 65% of the executives surveyed said the reality of paperless production and laboratory records is still 8 to 15 years in the future. The remainder of executives feels that this trend will affect industry sooner, with leading biopharmaceutical companies implementing such solutions within the next five to eight years.


Figure 1. LIMS system integration
Based on Tefen's consulting experience, we've found that some of the first business processes moving towards full automation are within the quality assurance function. In a few companies, we have seen deviation management and change control already conducted as paperless processes (at least partially). Many more companies are in the selection phase for such a system. An interesting finding, which could indicate confusion about 21 CFR Part 11 guidelines, is that nearly all companies are using some type of electronic database to manage deviations; however, only 20% of them are relying on a Part 11 compliant system.

The adoption of laboratory information management systems (LIMS) was also discussed. Although LIMS is a common fixture in most QC environments, there is wide variability in the extent of its implementation and integration with other systems. Where LIMS is installed, it is still mostly used as a data repository for test results, not as an operations management tool or source of metrics for continuous improvement. Figure 1 shows that LIMS integration with other systems, such as lab instrumentation, electronic document management systems, and training databases, is still in its infancy - even though this functionality is a major selling point of LIMS. Technical complexity, lack of previous experience, validation requirements, and competing IT priorities are preventing companies from moving in this direction.

The study also found that production automation and data collection are tied directly to the age of the plant, which often determines the extent of sophistication available. It seems most data collection occurring in manufacturing is focused on process parameters and not on operational performance.

Tefen concluded that although industry is starting to move in the right direction for business process automation, there is still a significant opportunity to enhance these isolated systems. Eventually, these tools will routinely provide key information and metrics that can drive continuous performance improvements in all key parts of the organization.

New Plants and Paperless Systems Marcus Webb and Gary Mitchell are responsible for systems engineering at IDEC Pharmaceuticals. They presented their company's automation plan for its new manufacturing facility nearing completion in Oceanside, CA. The result will be an almost fully automated plant, with electronic recipes and the ability to provide electronic batch records.

Webb and Mitchell outlined the selection process for their plant automation. Instead of using a typical RFP and bid process or relying on a single source (based on an existing vendor relationship), IDEC developed a more robust methodology. This involved developing a close relationship with a short list of vendors and sponsoring their development of detailed design specifications of the final product (not just responses to an RFP). Through this collaborative process, the technical and personality fits with vendors could be more effectively evaluated. IDEC's representatives said this technique - although costly and time consuming - guarantees better implementation of complex, long-term software projects.

Also at the meeting, Peter Watler, director of manufacturing for VaxGen, discussed his company's two new facilities. One is currently being built in Incheon, South Korea as part of a partnership with Celltrion. The second is a clinical facility in South San Francisco, CA.

VaxGen's relationship with Celltrion is something new for biopharmaceuticals and speaks to the desire to remain flexible in this risky industry. Through this partnership, Celltrion will manufacture product for VaxGen and also act as a contract manufacturer. The biggest challenge for VaxGen is helping Celltrion develop expertise in biopharmaceuticals - something new to South Korea.

In his presentation, Christian Węling, director of marketing and sales for Werum Software & Systems, focused on his company's electronic batch record (EBR) system, which is currently in use by a number of life sciences companies.

Most recently, Werum completed what is considered the first implementation of a truly paperless EBR system in the biopharmaceutical industry. According to Węling, the key to EBR implementation is performing a detailed upfront re-engineering and rationalization of the existing batch records before attempting automation.


Related Article


Future Meetings

Due to increased interest in the consortium, we have added an East Coast chapter. It conducted its first meeting - hosted by Wyeth BioPharma in Andover, MA - on November 6, 2003.

We are also planning to start a new European chapter in early 2004. For more information about the consortium and details on future meetings please e-mail us at
, or visit the consortium web site at www.tefen.com/consortium.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines
Source: BioPharm International,
Click here